"Our mission is to save patients’ lives and transform the management of medicine by cost-efficiently developing novel, innovative therapies for life-threatening conditions with significant unmet medical needs. We strive to achieve this goal through our commitment to excellence in research and clinical development"
PolyMedix is a clinical stage biotechnology company that is developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. Using our proprietary drug discovery platform, we have internally created a pipeline of innovative infectious disease and cardiovascular products that meet the following criteria:
- Address large market opportunities
- Therapeutic areas with efficient, inexpensive development paths
- Clear clinical endpoints
- Early clinical proof of concept
The lead compound in our infectious disease program is PMX-30063, the first drug of a completely new class of antibiotics, the defensin-mimetics. Our defensin-mimetic antibiotics are designed to imitate the mechanism of natural human immunity – the host defense proteins. By mimicking the mechanism of action of the host defense proteins, PMX-30063 works completely differently from known biochemical antibiotics, and exploits a method of bacterial cell killing that significantly reduces the risk of bacterial resistance. PMX-30063 has completed enrollment in a multi-national Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus bacteria, including methicillin-resistant S. aureus (MRSA).
The lead compound in our cardiovascular program is PMX-60056, which is an anticoagulant reversing agent designed to restore coagulation to help better manage the balance between preventing blood clots and mitigating bleeding in interventional cardiology procedures, as well as emergency situations where patients are on the anticoagulant drugs heparin and low molecular weight heparins (LMWH). In multiple clinical trials, PMX-60056 has met safety and efficacy endpoints and demonstrated clinical proof of concept. PMX-60056 is currently in a Phase 2 clinical trial to treat patients undergoing Percutaneous Coronary Intervention (PCI) and a Phase 1B/2 clinical trial to reverse the anticoagulant effect of the LMWH enoxaparin in healthy subjects.
Our preclinical portfolio includes next-generation defensin-mimetic compounds, which have shown potent activity targeting:
- Gram-negative bacteria
- Tuberculosis
- Malaria
- Foodborne pathogens
- Biodefense pathogens
- Fungal infections
We are leveraging our antimicrobial expertise by developing PolyCides®, antimicrobial additives to materials, such as cosmetics, plastics, textiles and dental products (PolyDentix™), to create self-sterilizing products and surfaces.